Methods: This study included 71 NSCLC patients who received EGFR-TKIs between 2013
and 2016. Adverse drug reaction of both erlotinib (n= 37) and gefitinib (n= 34) was …

The present network meta‑analysis aimed to compare the effectiveness and adverse effects
of gefitinib, erlotinib and icotinib in the treatment of patients with non‑small cell lung cancer …

Introduction: Epidermal growth factor receptor-tyrosine kinase inhibitors are used as
effective first-line and salvage therapy in the treatment of advanced non-small cell lung …

PURPOSE: The use of erlotinib after gefitinib failure in patients with non-small cell lung
cancer (NSCLC) is not clearly clarified in clinical practice. We sought to compile the …

PURPOSE: Gefitinib and erlotinib are potent EGFR TKIs, with antitumor activity. In this
randomized, single-center, non-comparative phase II trial, the efficacy and safety of gefitinib …

BACKGROUND: Gefitinib and erlotinib are commonly used for salvage therapy in patients
with nonsmall cell lung cancer (NSCLC) who have progressed on prior therapies. Although …

Background: An increasing number of patients with advanced non-small cell lung cancer
(NSCLC) have a poor prognosis and develop progressive disease after receiving …

Phase II Study of Erlotinib in Advanced Non–Small-Cell Lung Cancer After Failure of Gefitinib
Page 1 Phase II Study of Erlotinib in Advanced Non–Small-Cell Lung Cancer After Failure of …

Previous studies have demonstrated that both gefitinib and erlotinib are markedly effective
for the treatment of non-small-cell lung cancer (NSCLC) with somatic activating mutations of …

To evaluate the efficacy and safety of erlotinib for non-small cell lung cancer (NSCLC), we
performed a population-based observational study. The study involved 307 patients treated …